Singleron Biotechnologies, a yound and fast growing company, developing high-throughput single-cell multiomics platform products, recently completed Series A1 financing of more than $10M, less than two months following its oversubscribed Series A round that raised $30M. New investors include Softbank China Venture Capital (SBCVC) and two other US Dollar funds. Existing investors CDG Capital, Lilly Asia Ventures (LAV), and CDH Investments also participated in this funding round.
Founded in 2018, Singleron is dedicated to applying groundbreaking single cell analysis technologies to clinical diagnosis, drug development and health management. The company currently has offices and laboratories in Nanjing, Suzhou, US and Germany, and provides products and services to more than 200 hospitals, research institutes, and pharmaceutical companies. Singleron will invest the proceeds from recent rounds of financing to further develop single-cell platform products and their clinical applications, to accelerate the commercialization of its proprietary technologies, and to ramp up its international presence.
About CDG Capital
CDG Capital manages several funds including China Reform Conson Soochow Overseas Fund I L.P. CDG is a China-related overseas investment firm specializing in healthcare, industrials, and TMT sectors. Its portfolio companies in healthcare sector include Innovent, Akeso, TigerMed, RemeGen, MicroPort CardioFlow, Antengene, Grail.
Established in 2000, SB China Venture Capital (SBCVC) is a leading venture capital and private equity firm that manages both USD and RMB funds. Its investment focuses on high-tech, high growth companies in TMT, clean technology, healthcare, consumer/retail, and advanced manufacturing sectors; and it invests across all stages of companies.
About Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm founded in 2008, with offices in Shanghai, Hong Kong, and Palo Alto. Its vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.
Established in 2002, CDH Investments is one of the leading alternative investment fund managers focused on China today with over US$21 billion of assets under management. CDH has invested in more than 200 companies and has helped more than 70 companies to list successfully on international and China’s domestic stock exchanges. Many of portfolio companies are sector leaders, and, collectively, they play an important role in China’s economy. CDH’s core principle is to create value for all of its partners, including investors and portfolio companies.
Copyright © 2022 Singleron Biotechnologies